Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors

Pediatric Infectious Disease Journal

Volumn 23, Issue 1, 2004, Pages 15-22

  Englund, Janet A ^a   Raskino, Claire ^b   Vavro, Cindy ^c   Palumbo, Paul ^d   Ross, Lisa L ^c   McKinney, Ross ^e   Nikolic Djokic, Divna ^a   Colgrove, Robert C ^f   Baker, Carol J ^g  

^a UNIVERSITY OF CHICAGO   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c GLAXOSMITHKLINE   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Antiretroviral resistance; Antiretroviral therapy; Genotypic resistance; Pediatric human immunodeficiency virus; Syncytium inducing phenotype

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CODON; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GENE MUTATION; GENETICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LYMPHOCYTE COUNT; MALE; MUTATION; NONPARAMETRIC TEST; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RISK ASSESSMENT; TREATMENT OUTCOME; VIRUS LOAD;

CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DIDANOSINE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; MUTATION; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PROBABILITY; PROSPECTIVE STUDIES; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; STATISTICS, NONPARAMETRIC; VIRAL LOAD; ZIDOVUDINE;

EID: 0842282780     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000105105.80229.ba     Document Type: Article

References (29)

1. Englund JA, Baker CJ, Raskino C, et al. and the ACTG Study 152 Team. Didanosine and combination zidovudine/ didanosine are superior to zidovudine monotherapy for the initial treatment of symptomatic children infected with human immunodeficiency virus. N Engl J Med 1997;336:1704-12.
2. Hammer SM, Pedneault L. Antiretroviral resistance testing comes of age. Antivir Ther 2000;5:23-6.
3. De Gruttola V, Dix L, D'Aquila R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-8.
4. Schinazi RF, Larder BA, Mellors JW. Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 2000;8:65-91.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-ESA Panel. JAMA 2000;283:2417-26.
6. Ross L, Scarsella A, Raffanti S, et al. Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res Hum Retroviruses 2001;17:1107-15.
7. Palumbo PE, Raskino C, Fiscus S, et al. Predictive value of quantitative plasma HIV RNA and CD4 lymphocyte count for disease progression and response to therapy in HIV-infected infants. JAMA 1998;279:756-61.
8. Englund JA, Baker CJ, Raskino C, McKinney RE, Lifschitz MH, and the ACTG 152 Study Group. Clinical and laboratory characteristics of a large cohort of symptomatic HIV-infected infants and children. Pediatr Infect Dis J 1996;15:1025-36.
9. Michalski FJ. Diagnosis of human immunodeficiency virus infection: Progress in less than five years. Yale J Biol Med 1989;62:93-102.
10. Schwartz O, Henin Y, Marechal V, Montagnier L. A rapid and simple colorimetric test for the study of anti-HIV agents. AIDS Res Hum Retroviruses 1988;4:441-8.
11. US Department of Health and Human Services. ACTG virology manual for HIV laboratories. SIA 1-3, Publication 94-3828. Bethesda, MD: National Institutes of Health, 1994.
12. Kievits T, van Gemen B, van Strijp D, et al. NASBA isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection. J Virol Methods 1991; 35:273-86.
13. Sheskin, DJ. Handbook of parametric and nonparametric statistical procedures. Boca Raton: CRC Press, 1997.
14. Abrams EJ, Weedon J, Steketee RW, et al. Association of human immunodeficiency virus (HIV) load early in life with disease progression among HIV-infected infants: New York City Perinatal HIV Transmission Collaborative Study Group. J Infect Dis 1998;178:101-8.
15. + cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection: New York City Perinatal HIV Transmission Collaborative Study Group. J Pediatr 1997;130:890-7.
16. Larder BA, Coates KE, Kemp SD. Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J Virol 1991;65:5232-6.
17. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992;89:1934-8.
18. Kellam P, Boucher CA, Tijnagel JM, Larder BA. Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J Gen Virol 1994;75:341-51.
19. Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003;69:1-6.
20. Mellado MJ, Cilleruelo MJ, Ortiz M, et al. Viral phenotype, antiretroviral resistance and clinical evolution in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1997;16:1032-7.
21. Japour AJ, Wells S, D'Aquila RT, et al. Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. J Infect Dis 1995;171: 1172-9.
22. Balotta C, Colombo MC, Colucci G, et al. Plasma viremia and virus phenotype are correlates of disease progression in vertically human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J 1997;16:205-11.
23. Husson RN, Lan Y, Kojima E, Venzon D, Mitsuya H, McIntosh K. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. J Pediatr 1995;126:865-71.
24. von Seidlein L, Plaeger S, Dickover R, Krogstad P, Stiehm ER, Bryson Y. Primary human immunodeficiency virus type 1 infection during pregnancy associated with transmission of SI/MT-2 cell tropic virus and precipitous loss of CD4 cells in mother and infant. Pediatr Infect Dis J 1998;17: 528-30.
25. St. Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkof MS, Hamilton JD. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. The VA Cooperative Study Group. J Acquir Immune Defic Syndr 1993;6:891-7.
26. + cell depletion and progression to AIDS. Ann Intern Med 1993;118:681-8.
27. Barroga CF, Raskino C, Fangon MC, et al. The CCR5 delta 32 allele slows disease progression among HIV-1 infected children. J Infect Dis 2000;182:413-9.
28. Philpott S, Weiser B, Anastos K, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001;107:431-8.
29. Capparelli EV, Englund JA, Connor JD, et al. Population pharmacokinetics and pharmacodynamics of zidovudine in HIV-infected infants and children. J Clin Pharmacol 2003;43: 133-4.